UB Paderborn / Katalog / Suche / in CDI

Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy

American journal of physiology: Gastrointestinal and liver physiology, 2009-11, Vol.297 (5), p.G990-G998

2009

Link zum Volltext

Verfügbarkeit prüfen

Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling

Kidney international reports, 2021-05, Vol.6 (5), p.1379-1396

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic Targeting or Genetic Deletion of Mitochondrial Cyclophilin D Protects from NSAID-Induced Small Intestinal Ulceration in Mice

Toxicological sciences, 2010-11, Vol.118 (1), p.276-285

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 345: Novel RAS inhibitor, MCI-062, potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.345-345

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2707: A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2707-2707

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2731: A novel PDE10/beta-catenin inhibitor, MCI-048, suppresses lung tumorigenesis to block metastasis

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2731-2731

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1937-1937

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 478: A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.478-478

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract A30: Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC+/min-FCCC mouse model

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (3_Supplement), p.A30-A30

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract B21: PDE10A overexpression in colon cancer cells and tumors relative to normal colonocytes and colon mucosa

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (3_Supplement), p.B21-B21

2017

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

Cancer prevention research (Philadelphia, Pa.), 2021-11, Vol.14 (11), p.995-1008

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3864: A novel PDE10/β-catenin pathway inhibitor, MCI-030, for the treatment of colorectal cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3864-3864

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4822: Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4822-4822

2019

Link zum Volltext

Verfügbarkeit prüfen

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling

Oncotarget, 2017-09, Vol.8 (41), p.69264-69280

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract B54: Targeting constitutively active RAS signaling in high-grade serous ovarian carcinoma (HGSOC) with ADT-006, a novel small molecule that blocks RAS-effector interactions

Clinical cancer research, 2018-01, Vol.24 (1_Supplement), p.B54-B54

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1914: A novel celecoxib derivative that lacks COX-2 inhibition but displays potent colon tumor cell growth and PDE5 inhibitory activity

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1914-1914

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5159: Characterization of a novel class of RAS inhibitory compounds with potent anti-tumor activity

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5159-5159

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4972: Novel Ras inhibitor DC070-547 potently and selectively blocks Ras-RBD binding, EGFR binding to Ras signaling complex, EGFR activation of Ras signaling, and growth of Ras-driven lung tumor cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4972-4972

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5243: Novel non-COX inhibitory sulindac derivative with β-catenin suppressing activity reduces the formation of colorectal adenomas and adenocarcinomas in the APC +/min-FCCC mouse model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5243-5243

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1633: ADT-030, a novel dual-acting RAS and β-catenin inhibitor with robust antitumor activity

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1633-1633

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract B23: DC070-547, a novel Ras inhibitor potently and selectivity inhibits colon tumor growth in vitro and in vivo

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (3_Supplement), p.B23-B23

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4372: Phosphodiesterase 10A inhibition suppresses lung tumor cell growth by activating PKG to inhibit ras and Wnt signaling

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4372-4372

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1238: A novel Ras inhibitor potently and selectively suppresses lung tumor cell growth by blocking Ras-Raf binding

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1238-1238

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 331: Beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.331-331

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1140-1140

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy

Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling

Pharmacologic Targeting or Genetic Deletion of Mitochondrial Cyclophilin D Protects from NSAID-Induced Small Intestinal Ulceration in Mice

Abstract 345: Novel RAS inhibitor, MCI-062, potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS

Abstract 2707: A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity

Abstract 2731: A novel PDE10/beta-catenin inhibitor, MCI-048, suppresses lung tumorigenesis to block metastasis

Abstract 1937: Inhibition of a novel cancer target, PDE10, suppresses Wnt/β-catenin signaling and colon tumorigenesis: Benefits from combining with ornithine decarboxylase inhibitors

Abstract 478: A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy

Abstract A30: Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC+/min-FCCC mouse model

Abstract B21: PDE10A overexpression in colon cancer cells and tumors relative to normal colonocytes and colon mucosa

Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

Abstract 3864: A novel PDE10/β-catenin pathway inhibitor, MCI-030, for the treatment of colorectal cancer

Abstract 4822: Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors

Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling

Abstract B54: Targeting constitutively active RAS signaling in high-grade serous ovarian carcinoma (HGSOC) with ADT-006, a novel small molecule that blocks RAS-effector interactions

Abstract 1914: A novel celecoxib derivative that lacks COX-2 inhibition but displays potent colon tumor cell growth and PDE5 inhibitory activity

Abstract 5159: Characterization of a novel class of RAS inhibitory compounds with potent anti-tumor activity

Abstract 4972: Novel Ras inhibitor DC070-547 potently and selectively blocks Ras-RBD binding, EGFR binding to Ras signaling complex, EGFR activation of Ras signaling, and growth of Ras-driven lung tumor cells

Abstract 5243: Novel non-COX inhibitory sulindac derivative with β-catenin suppressing activity reduces the formation of colorectal adenomas and adenocarcinomas in the APC +/min-FCCC mouse model

Abstract 1633: ADT-030, a novel dual-acting RAS and β-catenin inhibitor with robust antitumor activity

Abstract B23: DC070-547, a novel Ras inhibitor potently and selectivity inhibits colon tumor growth in vitro and in vivo

Abstract 4372: Phosphodiesterase 10A inhibition suppresses lung tumor cell growth by activating PKG to inhibit ras and Wnt signaling

Abstract 1238: A novel Ras inhibitor potently and selectively suppresses lung tumor cell growth by blocking Ras-Raf binding

Abstract 331: Beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG

Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancer

Aktive Filter

Suchergebnisse filtern